草莓影视

Trending Topics
Sponsored Content

Webinar: Unlocking opioid settlement funding for public safety agencies

How to navigate the opioid funding landscape to secure resources for opioid abatement, reimbursement and remediation expenses

Sponsored by
Health Care Concept with Stethoscope on Green Marble Background

skodonnell/Getty Images

Register to attend this webinar on Tuesday, November 19, at 1 p.m. ET / 12 p.m. CT / 10 a.m. PT by completing the 鈥淩egister for this 草莓影视 Webinar鈥 box on this page!

Can鈥檛 make the date? Register anyway and we鈥檒l send you a recording after the event.

Nationwide, communities continue to battle the effects of the opioid crisis. Litigation brought by states against drug distributors, manufacturers and pharmacy chains has produced opioid settlement funding designed to bring relief to communities affected by the epidemic. The various funding mechanisms (how to request, how to apply and to who) is evolving and varies by state.

First responders are on the front line of this crisis treating overdose patients, securing illegal, dangerous drugs and managing the various scenarios related to opioid calls. For public safety agencies, including EMS, opioid settlement funding may be tapped for a variety of purposes. For this reason, public safety leaders must understand the basics of the settlements, how funds will be distributed and how your agency may be able to tap into funding in a responsible manner.

Join this webinar to learn:

  • How the opioid settlement was reached.
  • How funding will be distributed.
  • How funding can be used.
  • How Lexipol鈥檚 grants experts can help your agency navigate the opioid funding landscape and secure funding.

MEET THE SPEAKER:

EMS_Carlson_Corey.jpg

Corey Carlson

Corey Carlson is the EMS Segment Lead for Lexipol, where she researches legislation and grant opportunities for EMS sponsors and customers. Corey also consults with EMS GAP customers as a Grant Expert for Lexipol. She has over 22 years of experience working in the grant arena for first responders.